Prognostic Effect of pan-Immune-Inflammation Value Indices in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

BackgroundThis study aimed to investigate the association of pan-immune-inflammation value (PIV), PIV/HDL-C (high-density lipoprotein cholesterol), PIVLDL-C (low-density lipoprotein cholesterol) with the prognosis of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).MethodsA total of 1360 patients with ACS undergoing PCI were consecutively enrolled in this study. They were divided into major adverse cardiovascular events (MACEs) (n = 58) and non-MACEs (n = 1302) groups. The PIV, PIV/HDL-C, and PIVLDL-C values were measured. The endpoints were MACEs, including cardiogenic mortality, recurrence of myocardial infarction, in-stent restenosis, and rehospitalization for severe heart failure.ResultsThe multivariable Cox regression analysis showed that PIV ≥355.79 (hazard ratio [HR]: 2.006, 95% confidence interval [CI]: 1.165-3.455), PIV/HDL-C ≥ 282.86 (HR: 1.987, 95% CI: 1.119-3.527), and PIVLDL-C ≥ 1431.58 (HR: 2.071, 95% CI: 1.206-3.556) were all independent predictors of MACEs in patients with ACS undergoing PCI (all  < .05). The cumulative survival rates were significantly lower for patients with higher PIV, PIV/HDL-C, and PIVLDL-C than for patients with lower values of these indices (log-rank tests: all  < .05).ConclusionHigher PIV, PIV/HDL-C, and PIV*LDL-C were independent prognostic factors for patients with ACS undergoing PCI and may be novel biomarkers for predicting MACEs.